RE: Telegram Interview Q&A12 Aug 2025 11:05
Could someone ask him about
Grant of Haemostatic Hydrogel Patent
Following the publication of the Company's audited accounts for the year ended 31 December 2023 on 30 April 2024, which included an accounting impairment of the Company's plastic manufacturing plant in Slovenia, the Company announced the disposal of Graft Polymer d.o.o., its wholly owned Slovenian subsidiary, on 3 May 2024.
This disposal enables the Company to focus its attention and resources on its Graft Bio division, which represents, in the Directors' opinion, strong prospectivity through its intellectual property (IP), licensing agreements, and sales contracts.
The Company is pleased to announce the grant of patent P-202400066, titled "Dual hydrogel multi-crosslinking haemostatic composition and method of manufacturing thereof", to further strengthen the Company's IP portfolio.
The disclosed dual hydrogel multi-crosslinking haemostatic composition offers a groundbreaking solution for emergency haemostasis by amalgamating two distinct gels, each possessing unique cross-linking mechanisms and bioactive components. Gel A, containing sodium carboxymethylcellulose (Na-CMC) and tranexamic acid (TXA), is ionically cross-linked with calcium ions (Ca+), while Gel B, comprising cationic carboxymethyl chitosan (CMCS) and sodium alginate (Na-Alginate), undergoes electrostatic and ionic cross-linking with boron ions (B-).
Stored separately but applied together using a dual-chamber syringe, these gels intermix at the bleeding site, facilitating immediate formation of a final hydrogel with enhanced mechanical properties and adhesive strength.